ERCC6 and cancer: Intriguingly, although CS patients do not tend to develop cancer, mouse models with CSB mutations do show an elevated cancer incidence [38], suggesting that in some contexts, TCR loss can be oncogenic, but in humans, the syndrome’s lethal developmental effects manifest before cancer can arise.